Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oculis Holding AGOISE:OCS -1.10%26 5-Day RSI is 16.06 as of Jul. 31, 2026. GuruFocus rates OISE:OCS with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 1,418 Biotechnology companies, Oculis Holding AG ranks worse than 52.05% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Oculis Holding AG (OISE:OCS) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Oculis Holding AG 5-Day RSI Related Terms
OISE:OCS vs RIGL, GYRE, SGP: 5-Day RSI Comparison
For the Biotechnology subindustry, Oculis Holding AG's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oculis Holding AG 5-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oculis Holding AG's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Oculis Holding AG's 5-Day RSI falls into.
Oculis Holding AG (OISE:OCS) 5-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oculis Holding AG (OISE:OCS) has a 5-Day RSI of 16.06 as of Jul. 31, 2026. According to the industry distribution chart, Oculis Holding AG ranks #738 out of 1418 companies in the Biotechnology industry, placing it in the top 52%.
Is Oculis Holding AG's 5-Day RSI too high?
Oculis Holding AG's current 5-Day RSI is 16.06. The Biotechnology industry median 5-Day RSI is 39.62. Oculis Holding AG's value of 16.06 is 59.5% below this industry median. Based on the distribution chart, Oculis Holding AG ranks #738 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's 5-Day RSI compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Oculis Holding AG ranks #738 out of 1418 companies for 5-Day RSI. This places Oculis Holding AG in the lower half of its industry. The industry median 5-Day RSI is 39.62. Oculis Holding AG's value of 16.06 is 59.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 39.62, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oculis Holding AG's current 5-Day RSI of 16.06 is 59.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 39.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oculis Holding AG's current 5-Day RSI is 16.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OISE:OCS) has a current 5-Day RSI of 16.06. The current 5-Day RSI is 16.06 and 59.5% below the Biotechnology industry median of 39.62. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Oculis Holding AG (OISE:OCS), the current 5-Day RSI is 16.06 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score
Get the complete analysis for OISE:OCS
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:OCS has been successfully added to your 
